Heartseed Inc. and Novo Nordisk - in partnership since June 2021 - have announced that the first patient has been successfully dosed in a clinical study with HS-001, a cell therapy designed to restore ...
Novo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed by Japanese startup Heartseed. The Danish drugmaker has acquired exclusive rights outside ...
High blood pressure, which is also called hypertension, increases your risk of developing many serious health problems. According to the American Heart Association (AHA), high blood pressure can lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback